PIs can also synergize or have additive activity with other chemotherapies or myeloma-targeted agents, and PI-based combination regimens are ubiquitous in myeloma treatment algorithms for clinicians, which often comprise immunomodulatory drugs, monoclonal antibodies, and HDAC inhibitors. This evidence concerns the gene HDAC9 and plasma cell myeloma.